These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
229 related items for PubMed ID: 17465954
1. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY. Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954 [Abstract] [Full Text] [Related]
2. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY. Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000 [Abstract] [Full Text] [Related]
3. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, Kiss JE, Shyamala V, Busch MP, National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study (REDS-II). Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600 [Abstract] [Full Text] [Related]
4. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus. Bonvicini F, Gallinella G, Cricca M, Ambretti S, Delbarba S, Musiani M, Zerbini M. J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276 [Abstract] [Full Text] [Related]
5. Parvovirus B19 DNA in plasma pools and plasma derivatives. Schmidt I, Blümel J, Seitz H, Willkommen H, Löwer J. Vox Sang; 2001 Nov; 81(4):228-35. PubMed ID: 11903998 [Abstract] [Full Text] [Related]
6. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. Baylis SA, Shah N, Minor PD. J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727 [Abstract] [Full Text] [Related]
7. Human parvovirus PARV4 in clotting factor VIII concentrates. Fryer JF, Hubbard AR, Baylis SA. Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279 [Abstract] [Full Text] [Related]
8. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Nübling CM, Unkelbach U, Chudy M, Seitz R. Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414 [Abstract] [Full Text] [Related]
9. Blood donor screening for parvovirus B19 in Germany and Austria. Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP, Seifried E, Hourfar MK. Transfusion; 2007 Oct; 47(10):1775-82. PubMed ID: 17714425 [Abstract] [Full Text] [Related]
10. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Modrow S, Wenzel JJ, Schimanski S, Schwarzbeck J, Rothe U, Oldenburg J, Jilg W, Eis-Hübinger AM. Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933 [Abstract] [Full Text] [Related]
11. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group. Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442 [Abstract] [Full Text] [Related]
12. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d'Oiron R, Tchernia G. Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615 [Abstract] [Full Text] [Related]
13. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Schneider B, Becker M, Brackmann HH, Eis-Hübinger AM. Thromb Haemost; 2004 Oct; 92(4):838-45. PubMed ID: 15467916 [Abstract] [Full Text] [Related]
14. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Ke L, He M, Li C, Liu Y, Gao L, Yao F, Li J, Bi X, Lv Y, Wang J, Hirsch ML, Li W. Transfusion; 2011 Sep; 51(9):1909-18. PubMed ID: 21382040 [Abstract] [Full Text] [Related]
15. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB, Universal Data Collection Project Working Group. Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122 [Abstract] [Full Text] [Related]
16. [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience]. Petermann R, Piquet Y, Lapeyre M, Goujon N, Gauthier M, Lalanne V, Mouillot L, Tissier MH, Boiron JM. Transfus Clin Biol; 2010 Apr; 17(2):54-62. PubMed ID: 20674438 [Abstract] [Full Text] [Related]
17. Collaborative study for establishment of a European Pharmacopoeia Biological Reference Preparation (BRP) for B19 virus DNA testing of plasma pools by nucleic acid amplification technique. Nübling CM, Daas A, Buchheit KH. Pharmeuropa Bio; 2004 Jan; 2003(2):27-34. PubMed ID: 14960261 [Abstract] [Full Text] [Related]
18. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. Doyle S, Corcoran A. J Infect Dis; 2006 Jul 15; 194(2):154-8. PubMed ID: 16779720 [Abstract] [Full Text] [Related]
19. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools. Pichl L, Heitmann A, Herzog P, Oster J, Smets H, Schottstedt V. Transfusion; 2005 Jul 15; 45(7):1106-10. PubMed ID: 15987354 [Abstract] [Full Text] [Related]
20. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Plentz A, Hahn J, Knöll A, Holler E, Jilg W, Modrow S. Transfusion; 2005 Nov 15; 45(11):1811-5. PubMed ID: 16271109 [Abstract] [Full Text] [Related] Page: [Next] [New Search]